PL220838B1 - Kompozycja żelowa zawierająca retinoid i nadtlenek benzoilu, sposób jej wytwarzania i zastosowanie - Google Patents
Kompozycja żelowa zawierająca retinoid i nadtlenek benzoilu, sposób jej wytwarzania i zastosowanieInfo
- Publication number
- PL220838B1 PL220838B1 PL372270A PL37227002A PL220838B1 PL 220838 B1 PL220838 B1 PL 220838B1 PL 372270 A PL372270 A PL 372270A PL 37227002 A PL37227002 A PL 37227002A PL 220838 B1 PL220838 B1 PL 220838B1
- Authority
- PL
- Poland
- Prior art keywords
- composition
- benzoyl peroxide
- composition according
- acne
- retinoid
- Prior art date
Links
- 239000004342 Benzoyl peroxide Substances 0.000 title claims abstract description 92
- 235000019400 benzoyl peroxide Nutrition 0.000 title claims abstract description 92
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 title claims abstract description 90
- 150000004492 retinoid derivatives Chemical class 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 160
- 239000003349 gelling agent Substances 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000002537 cosmetic Substances 0.000 claims abstract description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 93
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 59
- 206010000496 acne Diseases 0.000 claims description 38
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 35
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- 239000012071 phase Substances 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 22
- 229960002916 adapalene Drugs 0.000 claims description 18
- 239000008346 aqueous phase Substances 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 16
- 239000004094 surface-active agent Substances 0.000 claims description 16
- 229920002507 Poloxamer 124 Polymers 0.000 claims description 15
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims description 15
- 229940093448 poloxamer 124 Drugs 0.000 claims description 15
- 238000009736 wetting Methods 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 14
- 235000011187 glycerol Nutrition 0.000 claims description 13
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 claims description 11
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims description 11
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 10
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 10
- 229920000053 polysorbate 80 Polymers 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- -1 benzonaphthalene retinoid Chemical class 0.000 claims description 9
- 229920001577 copolymer Polymers 0.000 claims description 9
- 238000013019 agitation Methods 0.000 claims description 8
- 229920002401 polyacrylamide Polymers 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 210000004209 hair Anatomy 0.000 claims description 7
- 230000003780 keratinization Effects 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 6
- 229920005682 EO-PO block copolymer Polymers 0.000 claims description 6
- WWAZUUULUNZNFE-UHFFFAOYSA-N [Na].NC(=O)C=C Chemical compound [Na].NC(=O)C=C WWAZUUULUNZNFE-UHFFFAOYSA-N 0.000 claims description 6
- 239000012072 active phase Substances 0.000 claims description 6
- 230000032683 aging Effects 0.000 claims description 6
- 239000003906 humectant Substances 0.000 claims description 6
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 206010013786 Dry skin Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 230000024245 cell differentiation Effects 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000009931 harmful effect Effects 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 229940068968 polysorbate 80 Drugs 0.000 claims description 4
- 206010000503 Acne cystic Diseases 0.000 claims description 3
- 201000004384 Alopecia Diseases 0.000 claims description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 3
- 102000034527 Retinoid X Receptors Human genes 0.000 claims description 3
- 241001303601 Rosacea Species 0.000 claims description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 3
- 230000003676 hair loss Effects 0.000 claims description 3
- 208000024963 hair loss Diseases 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 102000003702 retinoic acid receptors Human genes 0.000 claims description 3
- 108090000064 retinoic acid receptors Proteins 0.000 claims description 3
- 201000004700 rosacea Diseases 0.000 claims description 3
- 210000000106 sweat gland Anatomy 0.000 claims description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 210000000224 granular leucocyte Anatomy 0.000 claims description 2
- 208000013104 leukocyte disease Diseases 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 239000000499 gel Substances 0.000 description 27
- 239000008213 purified water Substances 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 17
- 239000003643 water by type Substances 0.000 description 15
- 239000013543 active substance Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 229920002125 Sokalan® Polymers 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 7
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 6
- 229960001631 carbomer Drugs 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 239000005711 Benzoic acid Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 206010020649 Hyperkeratosis Diseases 0.000 description 4
- 208000001126 Keratosis Diseases 0.000 description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000037336 dry skin Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 201000010153 skin papilloma Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010016936 Folliculitis Diseases 0.000 description 2
- 229920002509 Poloxamer 182 Polymers 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229940009868 aluminum magnesium silicate Drugs 0.000 description 2
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000009109 curative therapy Methods 0.000 description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940018602 docusate Drugs 0.000 description 2
- 229960000878 docusate sodium Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 238000013021 overheating Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 229940093426 poloxamer 182 Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- ZUEDYKQDCUKNJD-UHFFFAOYSA-N 2-methylpentadecane Chemical compound CCCCCCCCCCCCCC(C)C.CCCCCCCCCCCCCC(C)C ZUEDYKQDCUKNJD-UHFFFAOYSA-N 0.000 description 1
- SGRCVQDBWHCTIS-UHFFFAOYSA-N 2-nonanoyloxypropyl nonanoate Chemical compound CCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCC SGRCVQDBWHCTIS-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical class NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000218218 Ficus <angiosperm> Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000009693 Gingival Hyperplasia Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- 206010028703 Nail psoriasis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 208000031439 Striae Distensae Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- IFAGJNNYKJYUSJ-UHFFFAOYSA-N [Na].[Na].OCC(O)CO Chemical compound [Na].[Na].OCC(O)CO IFAGJNNYKJYUSJ-UHFFFAOYSA-N 0.000 description 1
- YEDTWOLJNQYBPU-UHFFFAOYSA-N [Na].[Na].[Na] Chemical compound [Na].[Na].[Na] YEDTWOLJNQYBPU-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003656 anti-hair-loss Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- KORSJDCBLAPZEQ-UHFFFAOYSA-N dicyclohexylmethane-4,4'-diisocyanate Chemical compound C1CC(N=C=O)CCC1CC1CCC(N=C=O)CC1 KORSJDCBLAPZEQ-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229920003111 hydroxyethyl cellulose HHX Polymers 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960001144 mizolastine Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0116747A FR2833841B1 (fr) | 2001-12-21 | 2001-12-21 | Gel comprenant au moins un retinoide et du peroxyde de benzoyle |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL372270A1 PL372270A1 (en) | 2005-07-11 |
| PL220838B1 true PL220838B1 (pl) | 2016-01-29 |
Family
ID=8870899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL372270A PL220838B1 (pl) | 2001-12-21 | 2002-12-09 | Kompozycja żelowa zawierająca retinoid i nadtlenek benzoilu, sposób jej wytwarzania i zastosowanie |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1458369B1 (enExample) |
| JP (2) | JP4889922B2 (enExample) |
| KR (1) | KR101014586B1 (enExample) |
| CN (1) | CN1329025C (enExample) |
| AR (1) | AR038026A1 (enExample) |
| AT (1) | ATE347354T1 (enExample) |
| AU (2) | AU2002364437B2 (enExample) |
| BR (1) | BRPI0214264B8 (enExample) |
| CA (1) | CA2466321C (enExample) |
| CY (1) | CY1107583T1 (enExample) |
| DE (2) | DE60216634T2 (enExample) |
| DK (1) | DK1458369T3 (enExample) |
| ES (1) | ES2275948T3 (enExample) |
| FR (2) | FR2833841B1 (enExample) |
| HU (1) | HU230439B1 (enExample) |
| MX (1) | MXPA04005918A (enExample) |
| PL (1) | PL220838B1 (enExample) |
| PT (1) | PT1458369E (enExample) |
| RU (1) | RU2320327C2 (enExample) |
| SI (1) | SI1458369T1 (enExample) |
| WO (1) | WO2003055472A1 (enExample) |
| ZA (1) | ZA200403759B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2833841B1 (fr) * | 2001-12-21 | 2005-07-22 | Galderma Res & Dev | Gel comprenant au moins un retinoide et du peroxyde de benzoyle |
| US7820186B2 (en) | 2001-12-21 | 2010-10-26 | Galderma Research & Development | Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
| EP1813312A3 (en) * | 2002-09-05 | 2010-03-24 | Galderma Research & Development | Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent |
| US7544674B2 (en) | 2002-10-25 | 2009-06-09 | Galderma S.A. | Topical skin care composition |
| CA2586798A1 (en) * | 2004-11-09 | 2006-05-18 | Imaginative Research Associates, Inc. | Retinoid solutions and formulations made therefrom |
| AU2006274541B2 (en) | 2005-08-02 | 2012-12-13 | Sol-Gel Technologies Ltd. | Metal oxide coating of water insoluble ingredients |
| FR2889662B1 (fr) * | 2005-08-11 | 2011-01-14 | Galderma Res & Dev | Emulsion de type huile-dans-eau pour application topique en dermatologie |
| FR2890314B1 (fr) * | 2005-09-02 | 2009-03-20 | Galderma Res & Dev | Compositiondepigmentante de la peau comprenant de l'adapalene au moins un agent depigmentant et au moins un agent anti-inflammatoire |
| WO2007052157A2 (en) * | 2005-09-02 | 2007-05-10 | Galderma Research & Development | Depigmenting composition for the skin, comprising adapalene, at least one depigmenting agent and at least one anti-inflammatory agent |
| BRPI0709674A2 (pt) | 2006-03-31 | 2011-12-06 | Stiefel Research Australia Pty Ltd. | gel de suspensão espumante |
| FR2901139B1 (fr) * | 2006-05-17 | 2009-03-20 | Galderma Res & Dev S N C Snc | Compositions comprenant au moins un derive de l'acide naphtoique et du peroxyde de benzoyle, leurs procedes de preparation, et leurs utilisations |
| WO2008006848A1 (en) * | 2006-07-13 | 2008-01-17 | Galderma Research & Development | Composition comprising a retinoid and benzoyl peroxide |
| US8080537B2 (en) | 2006-07-13 | 2011-12-20 | Galderma Research & Development | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
| FR2903604B1 (fr) * | 2006-07-13 | 2008-09-05 | Galderma Res & Dev S N C Snc | Composition comprenant un retinoide et du peroxyde de benzoyle |
| FR2903603B1 (fr) * | 2006-07-13 | 2009-03-20 | Galderma Res & Dev S N C Snc | Combinaison d'adapalene et de peroxyde de benzole dans le traitement de l'acne |
| FR2909000B1 (fr) * | 2006-11-28 | 2009-02-06 | Galderma Res & Dev S N C Snc | Compositions comprenant du peroxyde de benzoyle, au moins un derive de l'acide naphtoique et au moins un compose de type polymeres de polyurethane ou des derives de celui-ci, et leurs utilisations. |
| FR2910320B1 (fr) * | 2006-12-21 | 2009-02-13 | Galderma Res & Dev S N C Snc | Emulsion comprenant au moins un retinoide et du peroxyde de benzole |
| FR2910321B1 (fr) * | 2006-12-21 | 2009-07-10 | Galderma Res & Dev S N C Snc | Gel creme comprenant au moins un retinoide et du peroxyde de benzole |
| ES2546029T3 (es) | 2007-01-30 | 2015-09-17 | Galderma Research & Development | Uso de adapaleno y peróxido de benzoilo para el tratamiento a largo plazo del acné vulgar |
| BRPI0808163A2 (pt) | 2007-02-01 | 2014-11-04 | Sol Gel Technologies Ltd | Composição para aplicação tópica, métodos para tratar uma condição de superfície em um indivíduo, para preparar uma composição, e para usar o kit, e, kit |
| KR20090121291A (ko) | 2007-02-01 | 2009-11-25 | 솔-겔 테크놀로지스 리미티드 | 산화금속 코팅을 포함한 입자의 제조방법 및 산화금속 코팅을 포함한 입자 |
| EP1967180A1 (de) * | 2007-03-06 | 2008-09-10 | Almirall Hermal GmbH | Topische Zusammensetzung enthaltend einen Retinoid-Rezeptor-Agonist |
| FR2916966B1 (fr) * | 2007-06-11 | 2011-01-14 | Galderma Res & Dev | Compositions comprenant au moins un compose retinoide, un compose anti-irritant et du peroxyde de benzoyle, et leurs utilisations |
| FR2916975B1 (fr) * | 2007-06-11 | 2009-09-04 | Galderma Res & Dev | Compositions comprenant au moins un compose retinoide, un compose anti-irritant et du peroxyde de benzoyle, et leurs utilisations |
| EP2065032A1 (en) * | 2007-11-27 | 2009-06-03 | Galderma Research & Development | A method for producing adapalene gels |
| KR101538187B1 (ko) * | 2007-11-30 | 2015-07-22 | 갈데르마 리써어치 앤드 디벨로프먼트 | 하나 이상의 나프토산 유도체, 과산화 벤조일 및 하나 이상의 필름-형성제를 함유하는 조성물 |
| US8288434B2 (en) * | 2008-06-05 | 2012-10-16 | Dow Pharmaceutical Sciences, Inc. | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
| EA029534B1 (ru) | 2008-11-07 | 2018-04-30 | Клокс Текнолоджиз Инк. | Комбинация оксиданта и фотоактиватора для заживления ран |
| BR112012007798A2 (pt) * | 2009-10-07 | 2016-11-22 | Tagra Biotechnologies Ltd | microcápsulas estáveis e composição para aplicação tópica e método para a preparação de microcápsulas |
| BR112012009644A2 (pt) * | 2009-10-21 | 2015-09-29 | Dow Pharmaceutical Sciences | método para umedecer um pó contendo o peróxido de benzoíla |
| US20130131177A1 (en) | 2010-02-09 | 2013-05-23 | Galderma Research & Development | Use of a dermatological composition comprising a combination of adapalene and benzoyl peroxide which is intended for the treatment of acne in non-caucasian population with decrease of post-inflammatory hyperpigmentation |
| FR2969491B1 (fr) * | 2010-12-23 | 2013-07-12 | Galderma Res & Dev | Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant une combinaison d'adapalene et de bpo |
| FR2969492B1 (fr) * | 2010-12-23 | 2013-07-05 | Galderma Res & Dev | Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant de l'adapalene |
| US8563535B2 (en) | 2011-03-29 | 2013-10-22 | Kamal Mehta | Combination composition comprising benzoyl peroxide and adapalene |
| US20150126608A1 (en) | 2012-05-25 | 2015-05-07 | Galderma Research & Development | Treatment of preadolescent moderate acne vulgaris |
| BR112015010819B1 (pt) * | 2012-11-13 | 2019-12-17 | Galderma Sa | composição de lavagem tópica e uso da composição |
| US9687465B2 (en) | 2012-11-27 | 2017-06-27 | Sol-Gel Technologies Ltd. | Compositions for the treatment of rosacea |
| WO2015091828A1 (en) | 2013-12-19 | 2015-06-25 | Galderma Research & Development | Therapy regimen for treating severe acne related diseases |
| AU2015239688B2 (en) | 2014-04-01 | 2020-06-25 | Galderma Research & Development | Combination of adapalene and benzoyl peroxide for treating acne scars |
| RS61017B1 (sr) | 2014-07-25 | 2020-12-31 | Galderma Res & Dev | Kombinacija adapalena i benzoil peroksida za lečenje teških akni |
| US20180235924A1 (en) * | 2015-08-20 | 2018-08-23 | Sol-Gel Technologies Ltd. | Compositions for topical application comprising benzoyl peroxide and adapalene |
| WO2018080284A1 (ko) * | 2016-10-31 | 2018-05-03 | (주)동구바이오제약 | 여드름 치료용 약물의 생체이용률을 증진시키는 약학적 조성물 |
| CN106729722B (zh) * | 2016-11-21 | 2020-05-12 | 成都山信药业有限公司 | 一种制备稳定复方制剂的方法及复方制剂 |
| WO2019012537A1 (en) | 2017-07-12 | 2019-01-17 | Sol-Gel Technologies Ltd | COMPOSITIONS COMPRISING ENCAPSULATED TRETTINOIN |
| SG11202111028YA (en) * | 2019-04-04 | 2021-11-29 | Galderma Hoding Sa | Isopropylcarbonate benzoyl peroxide compositions and methods of use |
| JPWO2023112664A1 (enExample) * | 2021-12-14 | 2023-06-22 | ||
| WO2023177625A1 (en) * | 2022-03-14 | 2023-09-21 | Blue Hill Technologies Llc | Shelf-stable formulations of benzoyl peroxide and methods of producing same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2378523A1 (fr) * | 1977-01-26 | 1978-08-25 | Grupper Charles | Medicament pour le traitement de l'acne |
| US4189501A (en) * | 1977-10-07 | 1980-02-19 | A. H. C. Pharmacal, Inc. | Composition and method for the treatment of acne |
| LU85849A1 (fr) * | 1985-04-11 | 1986-11-05 | Cird | Derives benzonaphtaleniques,leur procede de preparation et leur application dans les domaines pharmaceutiques et cosmetiques |
| US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| FR2628319B1 (fr) * | 1988-03-09 | 1990-12-07 | Oreal | Compositions pharmaceutiques et cosmetiques a base de peroxyde de benzoyle et de sels d'ammonium quaternaires |
| DK0608353T3 (da) * | 1991-10-16 | 1996-07-01 | Richardson Vicks Inc | Vandig, kosmetisk gel med lav pH-værdi og indeholdende ikke-ioniske polyacrylamidderivater |
| US5470884A (en) * | 1994-05-19 | 1995-11-28 | Procter & Gamble | Anti-acne compositions |
| FR2785284B1 (fr) * | 1998-11-02 | 2000-12-01 | Galderma Res & Dev | Analogues de la vitamine d |
| FR2787322B1 (fr) * | 1998-12-18 | 2002-10-18 | Galderma Res & Dev | Emulsion huile-dans-eau comprenant un agent actif micronise et un systeme emulsionnant approprie |
| DE50014447D1 (de) * | 1999-12-20 | 2007-08-09 | Henkel Kgaa | Tablettierung verdickender systeme |
| FR2833841B1 (fr) * | 2001-12-21 | 2005-07-22 | Galderma Res & Dev | Gel comprenant au moins un retinoide et du peroxyde de benzoyle |
-
2001
- 2001-12-21 FR FR0116747A patent/FR2833841B1/fr not_active Expired - Fee Related
-
2002
- 2002-12-09 BR BRPI0214264A patent/BRPI0214264B8/pt not_active IP Right Cessation
- 2002-12-09 HU HU0500006A patent/HU230439B1/hu unknown
- 2002-12-09 CA CA2466321A patent/CA2466321C/fr not_active Expired - Fee Related
- 2002-12-09 JP JP2003556050A patent/JP4889922B2/ja not_active Expired - Lifetime
- 2002-12-09 CN CNB028258460A patent/CN1329025C/zh not_active Expired - Lifetime
- 2002-12-09 PT PT02799797T patent/PT1458369E/pt unknown
- 2002-12-09 SI SI200230454T patent/SI1458369T1/sl unknown
- 2002-12-09 EP EP02799797A patent/EP1458369B1/fr not_active Expired - Lifetime
- 2002-12-09 DE DE60216634T patent/DE60216634T2/de not_active Expired - Lifetime
- 2002-12-09 PL PL372270A patent/PL220838B1/pl unknown
- 2002-12-09 DE DE122008000041C patent/DE122008000041I1/de active Pending
- 2002-12-09 ES ES02799797T patent/ES2275948T3/es not_active Expired - Lifetime
- 2002-12-09 AU AU2002364437A patent/AU2002364437B2/en not_active Expired
- 2002-12-09 AT AT02799797T patent/ATE347354T1/de active
- 2002-12-09 RU RU2004122429/15A patent/RU2320327C2/ru active
- 2002-12-09 DK DK02799797T patent/DK1458369T3/da active
- 2002-12-09 KR KR1020047008461A patent/KR101014586B1/ko not_active Expired - Lifetime
- 2002-12-09 MX MXPA04005918A patent/MXPA04005918A/es active IP Right Grant
- 2002-12-09 WO PCT/FR2002/004233 patent/WO2003055472A1/fr not_active Ceased
- 2002-12-18 AR ARP020104930A patent/AR038026A1/es not_active Application Discontinuation
-
2004
- 2004-05-17 ZA ZA2004/03759A patent/ZA200403759B/en unknown
-
2007
- 2007-01-29 CY CY20071100120T patent/CY1107583T1/el unknown
-
2008
- 2008-06-05 FR FR08C0024C patent/FR08C0024I2/fr active Active
- 2008-11-21 AU AU2008246274A patent/AU2008246274B2/en not_active Expired
-
2010
- 2010-11-26 JP JP2010264093A patent/JP5478468B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101014586B1 (ko) | 하나 이상의 레티노이드 및 벤조일 퍼옥시드를 포함하는 겔 | |
| US8241649B2 (en) | Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide | |
| RU2454989C2 (ru) | Эмульсия, содержащая по меньшей мере один ретиноид и пероксид бензоила | |
| CA2656451A1 (en) | Composition comprising a retinoid and benzoyl peroxide | |
| FR2926218A1 (fr) | Composition comprenant un retinoide et du peroxyde de benzoyle disperse. | |
| PT1464321E (pt) | Composição de coloração para matérias ceratínicas humanas compreendendo um corante fluorescente e um silicone aminado, processo e utilização | |
| BRPI0713221B1 (pt) | composição, uso de uma composição e uso cosmético de uma composição | |
| HK1140160A (en) | Cream-gel comprising at least one retinoid and benzoyl peroxide |